Mirum Pharmaceuticals, Inc.
MIRM
|
$24.0
-1.72%
-1.75%
320K
|
Health Technology
(0.0% 1d) (-6.6% 1m) (-8.7% 1y) (0.0% 2d) (1.0% 3d) (3.6% 7d) (66.08% volume)
Earnings Calendar: 2024-03-06
Market Cap: $ 1,128,079,896
http://www.mirumpharma.com
Sec Filling | Patents | 33 employees
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
liver liver disease
add to watch list Paper trade email alert is off
Press-releases
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 02:00) - prnewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: -0.68%
H: 2.52%
C: 1.71%
report million reach treatment market
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 11, 2024
Published: 2024-04-11 (Crawled : 07:00) - biospace.com/
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: -0.35%
H: 1.98%
C: 1.25%
nasdaq pharmaceuticals grants
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
Published: 2024-04-02 (Crawled : 22:00) - biospace.com/
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: -1.3%
H: 0.7%
C: 0.36%
pruritus positive livmarli
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
SGMT | News | $4.15 -3.04% -3.13% 220K
|
Health Technology
|
| O: 6.65%
H: 18.5%
C: 8.52%
IPSC | $2.98 -4.79% -5.03% 130K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 1.58%
C: -9.48%
RPHM | $1.675 0.0% 140K
|
Professional, Scientific, and T...
|
| O: -1.81%
H: 4.91%
C: 2.45%
XOMA | $25.11 -3.76% -3.9% 8.2K
|
Health Technology
|
| O: 1.09%
H: 3.51%
C: -4.27%
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: 0.0%
H: 1.61%
C: 0.04%
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: 1.49%
H: 2.98%
C: -0.43%
fda pruritus approval treatment livmarli
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - March 5, 2024
Published: 2024-03-05 (Crawled : 14:30) - biospace.com/
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: 0.17%
H: 1.04%
C: -2.54%
pharmaceuticals
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
Published: 2024-02-29 (Crawled : 15:00) - biospace.com/
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: -1.04%
H: 4.87%
C: 0.42%
livmarli
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
Published: 2024-02-21 (Crawled : 00:00) - biospace.com/
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: -0.45%
H: 1.28%
C: -2.31%
conference pharmaceuticals financial results
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 11, 2024
Published: 2024-01-11 (Crawled : 07:00) - biospace.com/
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: 0.04%
H: 3.88%
C: 2.32%
nasdaq pharmaceuticals grants
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
Published: 2024-01-08 (Crawled : 16:00) - biospace.com/
MIRM | $24.0 -1.72% -1.75% 320K
|
Health Technology
|
| O: -1.39%
H: 0.43%
C: 0.21%
revenue pharmaceuticals
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10